Citadel Advisors
PCSA icon

Citadel Advisors’s Processa Pharmaceuticals PCSA Stock Holding History

Citadel Advisors’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-631
Closed -$106K – 15255
2023
Q4 		$106K Buy
631
+299
+90% +$66.7K ﹤0.01% 10865
2023
Q3 		$42.4K Sell
332
-234
-41% -$44.2K ﹤0.01% 11941
2023
Q2 		$141K Buy
+566
New +$167K ﹤0.01% 10424
2021
Q3 		– Sell
-20
Closed -$83K – 14432
2021
Q2 		$83K Sell
20
-6
-23% -$23.2K ﹤0.01% 13055
2021
Q1 		$143K Buy
+26
New +$121K ﹤0.01% 12104

Other funds holding PCSA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $144M AUM 19.29% 1-Year Est. Return

Citadel Advisors's PCSA Position: Q1 2024 in Review

Citadel Advisors sold out of Processa Pharmaceuticals (PCSA) in Q1 2024, closing a stake of 631 shares — an estimated $106K sold.

Citadel Advisors first reported a position in PCSA in Q1 2021 and held it in 5 quarters. The position peaked at $143K in Q1 2021. 9 funds tracked by Wall St. Rank hold PCSA as of Q1 2024.

  • Citadel Advisors reported no remaining Processa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 631 Processa Pharmaceuticals shares in Q1 2024, an estimated $106K.
  • Citadel Advisors first reported a position in Processa Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Citadel Advisors's Processa Pharmaceuticals position peaked at $143K in Q1 2021.
  • 9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.